{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:36:09Z","timestamp":1789763769378,"version":"4.0.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Intracerebral amyloid \u03b2 (A\u03b2) accumulation is considered the initial observable event in the pathological process of Alzheimer\u2019s disease (AD). Efficient screening for amyloid pathology is critical for identifying patients for early treatment. This study developed machine learning models to classify positron emission tomography (PET) A\u03b2-positivity in participants with preclinical and prodromal AD using data accessible to primary care physicians.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective observational study assessed the classification performance of combinations of demographic characteristics, routine blood test results, and cognitive test scores to classify PET A\u03b2-positivity using machine learning. Participants with mild cognitive impairment (MCI) or normal cognitive function who visited Oita University Hospital or had participated in the USUKI study and met the study eligibility criteria were included. The primary endpoint was assessment of the classification performance of the presence or absence of intracerebral A\u03b2 accumulation using five machine learning models (i.e., five combinations of variables), each constructed with three classification algorithms, resulting in a total of 15 patterns. L2-regularized logistic regression, and kernel Support Vector Machine (SVM) and Elastic Net algorithms were used to construct the classification models using 34 pre-selected variables (12 demographic characteristics, 11 blood test results, 11 cognitive test results).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Data from 262 records (260 unique participants) were analyzed. The mean (standard deviation [SD]) participant age was 73.8 (7.8) years. Using L2-regularized logistic regression, the mean receiver operating characteristic (ROC) area under the curve (AUC) (SD) in Model 0 (basic demographic characteristics) was 0.67 (0.01). Classification performance was similar in Model 1 (basic demographic characteristics and Mini Mental State Examination [MMSE] subscores) and Model 2 (demographic characteristics and blood test results) with a cross-validated mean ROC AUC (SD) of 0.70 (0.01) for both. Model 3 (demographic characteristics, blood test results, MMSE subscores) and Model 4 (Model 3 and ApoE4 phenotype) showed improved performance with a mean ROC AUC (SD) of 0.73 (0.01) and 0.76 (0.01), respectively. In models using blood test results, thyroid-stimulating hormone and mean corpuscular volume tended to be the largest contributors to classification. Classification performances were similar using the SVM and Elastic Net algorithms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The machine learning models used in this study were useful for classifying PET A\u03b2-positivity using data from routine physician visits.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>UMIN Clinical Trials Registry (UMIN000051776, registered on 31\/08\/2023).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13195-024-01650-1","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:36:22Z","timestamp":1737444982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study"],"prefix":"10.1186","volume":"17","author":[{"given":"Noriyuki","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruaki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ataka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"4","key":"1650_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/alz.12638","volume":"18","author":"2022 Alzheimer\u2019s disease facts and figures","year":"2022","unstructured":"2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2022;18(4):700\u201389. https:\/\/doi.org\/10.1002\/alz.12638.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1650_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312. https:\/\/doi.org\/10.1016\/j.cell.2019.09.001.","journal-title":"Cell"},{"issue":"4","key":"1650_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"10284","key":"1650_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(20)32205-4.","journal-title":"Lancet"},{"key":"1650_CR5","doi-asserted-by":"publisher","unstructured":"Dhillon S. Aducanumab: First Approval. Drugs. 2021;81(12):1437-43. https:\/\/doi.org\/10.1007\/s40265-021-01569-z. Erratum in: Drugs. 2021;81(14):1701. https:\/\/doi.org\/10.1007\/s40265-021-01590-2.","DOI":"10.1007\/s40265-021-01569-z 10.1007\/s40265-021-01590-2"},{"issue":"4","key":"1650_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Lecanemab: first approval. Drugs. 2023;83(4):359\u201365. https:\/\/doi.org\/10.1007\/s40265-023-01851-2.","journal-title":"Drugs"},{"key":"1650_CR7","unstructured":"Eli Lilly and Company. KISUNLA (donanemab-azbt) prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761248s000lbl.pdf. Accessed 29 Aug 2024."},{"key":"1650_CR8","unstructured":"Eisai Inc. LEQEMBI\u00ae (lecanemab-irmb) prescribing information. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269Orig1s001lbl.pdf. Accessed 29 Aug 2024."},{"key":"1650_CR9","unstructured":"Biogen Inc. and Eisai Inc. ADUHELM\u00ae (aducanumab-avwa) injection prescribing information. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761178s005lbl.pdf. Accessed 29 Aug 2024."},{"issue":"1","key":"1650_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13195-023-01363-x","volume":"15","author":"N Kimura","year":"2023","unstructured":"Kimura N, Aota T, Aso Y, Yabuuchi K, Sasaki K, Masuda T, et al. Predicting Positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors. Alzheimers Res Ther. 2023;15(1):212. https:\/\/doi.org\/10.1186\/s13195-023-01363-x.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1650_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamaneurol.2021.5225","volume":"79","author":"CB Young","year":"2022","unstructured":"Young CB, Mormino EC. Prevalence rates of amyloid positivity\u2013updates and relevance. JAMA Neurol. 2022;79(3):225\u20137. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5225.","journal-title":"JAMA Neurol"},{"issue":"6393","key":"1650_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/359325a0","volume":"359","author":"P Seubert","year":"1992","unstructured":"Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer\u2019s beta-peptide from biological fluids. Nature. 1992;359(6393):325\u20137. https:\/\/doi.org\/10.1038\/359325a0.","journal-title":"Nature"},{"issue":"3","key":"1650_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306\u201319. https:\/\/doi.org\/10.1002\/ana.20009.","journal-title":"Ann Neurol"},{"issue":"11","key":"1650_CR14","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/archneurol.2011.150","volume":"68","author":"AS Fleisher","year":"2011","unstructured":"Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404\u201311. https:\/\/doi.org\/10.1001\/archneurol.2011.150.","journal-title":"Arch Neurol"},{"issue":"8","key":"1650_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","volume":"75","author":"RO Roberts","year":"2018","unstructured":"Roberts RO, Aakre JA, Kremers WK, Vassilaki M, Knopman DS, Mielke MM, et al. Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting. JAMA Neurol. 2018;75(8):970\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0629.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1650_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00406-022-01439-z","volume":"273","author":"J Contador","year":"2023","unstructured":"Contador J, Vargas-Mart\u00ednez AM, Sanchez-Valle R, Trapero-Bertran M, Llad\u00f3 A. Cost-effectiveness of Alzheimer\u2019s disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. Eur Arch Psychiatry Clin Neurosci. 2023;273(1):243\u201352. https:\/\/doi.org\/10.1007\/s00406-022-01439-z.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1650_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.trci.2019.06.001","volume":"5","author":"R Wittenberg","year":"2019","unstructured":"Wittenberg R, Knapp M, Karagiannidou M, Dickson J, Schott JM. Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer\u2019s disease patients. Alzheimers Dement Transl Res Clin Interv. 2019;5:382\u20137. https:\/\/doi.org\/10.1016\/j.trci.2019.06.001.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"4","key":"1650_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/mp.2013.40","volume":"19","author":"SC Burnham","year":"2014","unstructured":"Burnham SC, Faux NG, Wilson W, Laws SM, Ames D, Bedo J, et al. Alzheimer\u2019s Disease Neuroimaging Initiative; Australian imaging, biomarkers and Lifestyle Study Research Group. A blood-based predictor for neocortical A\u03b2 burden in Alzheimer\u2019s disease: results from the AIBL study. Mol Psychiatry. 2014;19(4):519\u201326. https:\/\/doi.org\/10.1038\/mp.2013.40.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"1650_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149\u201356. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1650_CR20","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H, Allu\u00e9 JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11):1375\u201382. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180. Erratum. In: JAMA Neurol. 2023;80(4):422.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1650_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14283\/jpad.2021.70","volume":"9","author":"C Udeh-Momoh","year":"2022","unstructured":"Udeh-Momoh C, Zheng B, Sandebring-Matton A, Novak G, Kivipelto M, J\u00f6nsson L, et al. Blood derived amyloid biomarkers for Alzheimer\u2019s disease prevention. J Prev Alzheimers Dis. 2022;9(1):12\u201321. https:\/\/doi.org\/10.14283\/jpad.2021.70.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"1650_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","volume":"14","author":"AL Benedet","year":"2022","unstructured":"Benedet AL, Brum WS, Hansson O, Karikari TK, Zimmer ER, Zetterberg H, et al. Alzheimer\u2019s disease neuroimaging initiative. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14(1):26. https:\/\/doi.org\/10.1186\/s13195-021-00942-0.","journal-title":"Alzheimers Res Ther"},{"key":"1650_CR23","doi-asserted-by":"publisher","unstructured":"Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, et al; Alzheimer's Disease Neuroimaging Initiative (ADNI); Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma A\u03b2 as a Predictor of Amyloid Positivity in Alzheimer's Disease Project Team. Comparative analytical performance of multiple plasma A\u03b242 and A\u03b240 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimers Dement. 2022:10.1002\/alz.12697. https:\/\/doi.org\/10.1002\/alz.12697. Epub ahead of print.","DOI":"10.1002\/alz.12697"},{"key":"1650_CR24","doi-asserted-by":"publisher","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Amyloid Biomarker Study Group, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924\u201338. https:\/\/doi.org\/10.1001\/jama.2015.4668.","DOI":"10.1001\/jama.2015.4668"},{"key":"1650_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.dadm.2017.01.005","volume":"7","author":"CY Santos","year":"2017","unstructured":"Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: a review and synthesis. Alzheimers Dement (Amst). 2017;7:69\u201387. https:\/\/doi.org\/10.1016\/j.dadm.2017.01.005.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"12","key":"1650_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723\u201338. https:\/\/doi.org\/10.1038\/nrn3114.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"1650_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042022","volume":"22","author":"LO Soto-Rojas","year":"2021","unstructured":"Soto-Rojas LO, Pacheco-Herrero M, Mart\u00ednez-G\u00f3mez PA, Campa-C\u00f3rdoba BB, Ap\u00e1tiga-P\u00e9rez R, Villegas-Rojas MM, et al. The neurovascular unit dysfunction in Alzheimer\u2019s disease. Int J Mol Sci. 2021;22(4): 2022. https:\/\/doi.org\/10.3390\/ijms22042022.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1650_CR28","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.neurobiolaging.2011.10.002","volume":"33","author":"BR Reed","year":"2012","unstructured":"Reed BR, Marchant NL, Jagust WJ, Stocker H, Holleczek B, Beyreuther K, et al. Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging. 2012;33(9):1979\u201387. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.10.002.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"1650_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00401-023-02559-z","volume":"145","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, He CY, Tian DY, Chen SH, Ren JR, Sun HL, et al. Physiological \u03b2-amyloid clearance by the liver and its therapeutic potential for Alzheimer\u2019s disease. Acta Neuropathol. 2023;145(6):717\u201331. https:\/\/doi.org\/10.1007\/s00401-023-02559-z.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1650_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-190848","volume":"75","author":"MF Bassendine","year":"2020","unstructured":"Bassendine MF, Taylor-Robinson SD, Fertleman M, Khan M, Neely D. Is Alzheimer\u2019s disease a liver disease of the brain? J Alzheimers Dis. 2020;75(1):1\u201314. https:\/\/doi.org\/10.3233\/JAD-190848.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1650_CR31","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1007\/s12035-016-9826-1","volume":"54","author":"YR Wang","year":"2017","unstructured":"Wang YR, Wang QH, Zhang T, Liu YH, Yao XQ, Zeng F, et al. Associations between hepatic functions and plasma amyloid-beta levels-implications for the capacity of liver in peripheral amyloid-beta clearance. Mol Neurobiol. 2017;54(3):2338\u201344. https:\/\/doi.org\/10.1007\/s12035-016-9826-1.","journal-title":"Mol Neurobiol"},{"issue":"10","key":"1650_CR32","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1038\/s41380-021-01073-6","volume":"26","author":"DY Tian","year":"2021","unstructured":"Tian DY, Cheng Y, Zhuang ZQ, He CY, Pan QG, Tang MZ, et al. Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer\u2019s disease. Mol Psychiatry. 2021;26(10):6074\u201382. https:\/\/doi.org\/10.1038\/s41380-021-01073-6.","journal-title":"Mol Psychiatry"},{"issue":"9","key":"1650_CR33","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1007\/s12035-023-03420-w","volume":"60","author":"HL Sun","year":"2023","unstructured":"Sun HL, Yao XQ, Lei L, Jin WS, Bai YD, Zeng GH, et al. Associations of blood and cerebrospinal fluid A\u03b2 and tau levels with renal function. Mol Neurobiol. 2023;60(9):5343\u201351. https:\/\/doi.org\/10.1007\/s12035-023-03420-w.","journal-title":"Mol Neurobiol"},{"issue":"2","key":"1650_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3233\/JAD-221107","volume":"92","author":"JR Ren","year":"2023","unstructured":"Ren JR, Wang Z, Cheng Y, He CY, Jian JM, Fan DY, et al. Associations between plasma klotho with renal function and cerebrospinal fluid amyloid-\u03b2 levels in Alzheimer\u2019s disease: the Chongqing ageing & dementia study. J Alzheimers Dis. 2023;92(2):477\u201385. https:\/\/doi.org\/10.3233\/JAD-221107.","journal-title":"J Alzheimers Dis"},{"key":"1650_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.815063","volume":"13","author":"JH Kim","year":"2022","unstructured":"Kim JH, Lee HS, Kim YH, Kwon MJ, Kim JH, Min CY, et al. The association between thyroid diseases and Alzheimer\u2019s disease in a national health screening cohort in Korea. Front Endocrinol (Lausanne). 2022;13: 815063. https:\/\/doi.org\/10.3389\/fendo.2022.815063.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"46","key":"1650_CR36","doi-asserted-by":"publisher","first-page":"30366","DOI":"10.1074\/jbc.273.46.30366","volume":"273","author":"B Belandia","year":"1998","unstructured":"Belandia B, Latasa MJ, Villa A, Pascual A. Thyroid hormone negatively regulates the transcriptional activity of the beta-amyloid precursor protein gene. J Biol Chem. 1998;273(46):30366\u201371. https:\/\/doi.org\/10.1074\/jbc.273.46.30366.","journal-title":"J Biol Chem"},{"issue":"12","key":"1650_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243227","volume":"15","author":"Y Chen","year":"2020","unstructured":"Chen Y, Ma CN, Luo L, Yin J, Gao Z, Yu Z, et al. The cross-sectional association between mean corpuscular volume level and cognitive function in Chinese over 45 years old: evidence from the China Health and Retirement Longitudinal Study. PLoS ONE. 2020;15(12): e0243227. https:\/\/doi.org\/10.1371\/journal.pone.0243227.","journal-title":"PLoS ONE"},{"issue":"9","key":"1650_CR38","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1002\/alz.13088","volume":"19","author":"YX Qiang","year":"2023","unstructured":"Qiang YX, Deng YT, Zhang YR, Wang HF, Zhang W, Dong Q, et al. Associations of blood cell indices and anemia with risk of incident dementia: a prospective cohort study of 313,448 participants. Alzheimers Dement. 2023;19(9):3965\u201376. https:\/\/doi.org\/10.1002\/alz.13088.","journal-title":"Alzheimers Dement"},{"key":"1650_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.625511","volume":"13","author":"JW Kim","year":"2021","unstructured":"Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Ko K, et al. Blood hemoglobin, in-vivo Alzheimer pathologies, and cognitive impairment: a cross-sectional study. Front Aging Neurosci. 2021;13: 625511. https:\/\/doi.org\/10.3389\/fnagi.2021.625511.","journal-title":"Front Aging Neurosci"},{"issue":"10113","key":"1650_CR40","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/S0140-6736(17)31363-6","volume":"390","author":"G Livingston","year":"2017","unstructured":"Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673\u2013734. https:\/\/doi.org\/10.1016\/S0140-6736(17)31363-6.","journal-title":"Lancet"},{"issue":"10248","key":"1650_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(20)30367-6\u00a0Erratum in: Lancet. 2023;402(10408):1132. https:\/\/doi.org\/10.1016\/S0140-6736(23)02043-3","journal-title":"Lancet"},{"issue":"3","key":"1650_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1212\/WNL.0b013e318225aaa9","volume":"77","author":"RC Shah","year":"2011","unstructured":"Shah RC, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Hemoglobin level in older persons and incident Alzheimer disease: prospective cohort analysis. Neurology. 2011;77(3):219\u201326. https:\/\/doi.org\/10.1212\/WNL.0b013e318225aaa9.","journal-title":"Neurology"},{"key":"1650_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.888946","volume":"14","author":"LT Huang","year":"2022","unstructured":"Huang LT, Zhang CP, Wang YB, Wang JH. Association of peripheral blood cell profile with Alzheimer\u2019s disease: a meta-analysis. Front Aging Neurosci. 2022;14: 888946. https:\/\/doi.org\/10.3389\/fnagi.2022.888946.","journal-title":"Front Aging Neurosci"},{"key":"1650_CR44","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jsbmb.2016.03.012","volume":"160","author":"BC Riedel","year":"2016","unstructured":"Riedel BC, Thompson PM, Brinton RD, Age. APOE and sex: triad of risk of Alzheimer\u2019s disease. J Steroid Biochem Mol Biol. 2016;160:134\u201347. https:\/\/doi.org\/10.1016\/j.jsbmb.2016.03.012.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"1650_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13195-024-01415-w","volume":"16","author":"E Moradi","year":"2024","unstructured":"Moradi E, Prakash M, Hall A, Solomon A, Strange B, Tohka J. Alzheimer\u2019s disease neuroimaging initiative. Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals. Alzheimers Res Ther. 2024;16(1):46. https:\/\/doi.org\/10.1186\/s13195-024-01415-w.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1650_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3233\/JAD-220776","volume":"91","author":"WY Tan","year":"2023","unstructured":"Tan WY, Hargreaves C, Chen C, Hilal S. A machine learning approach for early diagnosis of cognitive impairment using population-based data. J Alzheimers Dis. 2023;91(1):449\u201361. https:\/\/doi.org\/10.3233\/JAD-220776.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1650_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13195-023-01328-0","volume":"15","author":"Y Diao","year":"2023","unstructured":"Diao Y, Lanz B, Jelescu IO. Subject classification and cross-time prediction based on functional connectivity and white matter microstructure features in a rat model of Alzheimer\u2019s using machine learning. Alzheimers Res Ther. 2023;15(1):193. https:\/\/doi.org\/10.1186\/s13195-023-01328-0.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1650_CR48","doi-asserted-by":"publisher","first-page":"7633","DOI":"10.1038\/s41598-024-58223-3","volume":"14","author":"Y Momota","year":"2024","unstructured":"Momota Y, Bun S, Hirano J, Kamiya K, Ueda R, Iwabuchi Y, et al. Amyloid-\u03b2 prediction machine learning model using source-based morphometry across neurocognitive disorders. Sci Rep. 2024;14(1):7633. https:\/\/doi.org\/10.1038\/s41598-024-58223-3.","journal-title":"Sci Rep"},{"issue":"3","key":"1650_CR49","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"key":"1650_CR50","unstructured":"Oita University. Department of Neurology. Faculty of Medicine. FY2023 3rd Medical School Ethics Committee (Rapid review). Report of deliberation results and summary of proceedings. [In Japanese] https:\/\/www.med.oita-u.ac.jp\/joho\/rinri\/giji_gaiyo\/rinri\/2023\/jin-no03.pdf. Accessed 6 July 2024."},{"key":"1650_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00401","volume":"10","author":"N Kimura","year":"2019","unstructured":"Kimura N, Aso Y, Yabuuchi K, Ishibashi M, Hori D, Sasaki Y, et al. Modifiable lifestyle factors and cognitive function in older people: a cross-sectional observational study. Front Neurol. 2019;10: 401. https:\/\/doi.org\/10.3389\/fneur.2019.00401.","journal-title":"Front Neurol"},{"issue":"6","key":"1650_CR52","doi-asserted-by":"publisher","first-page":"e205719","DOI":"10.1001\/jamanetworkopen.2020.5719","volume":"3","author":"N Kimura","year":"2020","unstructured":"Kimura N, Aso Y, Yabuuchi K, Ishibashi M, Hori D, Sasaki Y, et al. Association of modifiable lifestyle factors with cortical amyloid burden and cerebral glucose metabolism in older adults with mild cognitive impairment. JAMA Netw Open. 2020;3(6):e205719. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.5719.","journal-title":"JAMA Netw Open"},{"key":"1650_CR53","unstructured":"Scikit-learn. QuantileTransformer. 2023. https:\/\/scikit-learn.org\/stable\/modules\/generated\/sklearn.preprocessing.QuantileTransformer.html. Accessed 6 Jul 2024."},{"issue":"11","key":"1650_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","volume":"36","author":"MB Kursa","year":"2010","unstructured":"Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J Stat Softw. 2010;36(11):1\u201313. https:\/\/doi.org\/10.18637\/jss.v036.i11.","journal-title":"J Stat Softw"},{"key":"1650_CR55","first-page":"177","volume":"20","author":"A Fisher","year":"2019","unstructured":"Fisher A, Rudin C, Dominici F. All models are wrong, but many are useful: learning a variable\u2019s importance by studying an entire class of prediction models simultaneously. J Mach Learn Res. 2019;20:177.","journal-title":"J Mach Learn Res"},{"key":"1650_CR56","unstructured":"Lundberg SM, Lee SI. A unified approach to interpreting model predictions. In: Advances in neural information processing systems. 2017. https:\/\/papers.nips.cc\/paper_files\/paper\/2017\/hash\/8a20a8621978632d76c43dfd28b67767-Abstract.html. Accessed 6 Jul 2024."},{"key":"1650_CR57","unstructured":"Molnar C. Interpretable machine learning: a guide for making black box models explainable, 2nd ed. 2022. https:\/\/christophm.github.io\/interpretable-ml-book\/. Accessed 6 Jul 2024."},{"issue":"1","key":"1650_CR58","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13195-024-01478-9","volume":"16","author":"AJ Mendes","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Zetterberg H, Abramowicz M. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients. Alzheimers Res Ther. 2024;16(1):110. https:\/\/doi.org\/10.1186\/s13195-024-01478-9.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1650_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","volume":"101","author":"D Alcolea","year":"2023","unstructured":"Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lle\u00f3 A. Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist. Neurology. 2023;101(4):172\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000207193.","journal-title":"Neurology"},{"issue":"1","key":"1650_CR60","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13195-024-01477-w","volume":"16","author":"M Koivum\u00e4ki","year":"2024","unstructured":"Koivum\u00e4ki M, Ekblad L, Lantero-Rodriguez J. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE \u03b54-enriched cognitively unimpaired elderly. Alzheimers Res Ther. 2024;16(1):112. https:\/\/doi.org\/10.1186\/s13195-024-01477-w.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1650_CR61","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13195-023-01296-5","volume":"15","author":"S Bun","year":"2023","unstructured":"Bun S, Ito D, Tezuka T, Kubota M, Ueda R, Takahata K, et al. Performance of plasma A\u03b242\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status. Alzheimers Res Ther. 2023;15(1):149. https:\/\/doi.org\/10.1186\/s13195-023-01296-5.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"1650_CR62","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359\u201362. https:\/\/doi.org\/10.1038\/nm1653.","journal-title":"Nat Med"},{"issue":"2","key":"1650_CR63","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jpm10020020","volume":"10","author":"E Angelopoulou","year":"2020","unstructured":"Angelopoulou E, Paudel YN, Shaikh MF, Piperi C, Flotillin. A promising biomarker for Alzheimer\u2019s disease. J Pers Med. 2020;10(2):20. https:\/\/doi.org\/10.3390\/jpm10020020.","journal-title":"J Pers Med"},{"issue":"4","key":"1650_CR64","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.3233\/JAD-190908","volume":"72","author":"M Abdullah","year":"2019","unstructured":"Abdullah M, Kimura N, Akatsu H, Hashizume Y, Ferdous T, Tachita T, et al. Flotillin is a novel diagnostic blood marker of Alzheimer\u2019s disease. J Alzheimers Dis. 2019;72(4):1165\u201376. https:\/\/doi.org\/10.3233\/JAD-190908.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1650_CR65","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JAD-191016","volume":"73","author":"K Abe","year":"2020","unstructured":"Abe K, Shang J, Shi X, Yamashita T, Hishikawa N, Takemoto M, et al. A new serum biomarker set to detect mild cognitive impairment and Alzheimer\u2019s disease by peptidome technology. J Alzheimers Dis. 2020;73(1):217\u201327. https:\/\/doi.org\/10.3233\/JAD-191016.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1650_CR66","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","volume":"13","author":"S Bayoumy","year":"2021","unstructured":"Bayoumy S, Verberk IMW, den Dulk B, Hussainali Z, Zwan M, van der Flier WM, et al. Clinical and analytical comparison of six simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimers Res Ther. 2021;13(1):198. https:\/\/doi.org\/10.1186\/s13195-021-00939-9.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"1650_CR67","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","volume":"15","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Zetterberg H, Blennow K, Brix B, Stomrud E. Alzheimer\u2019s Disease Neuroimaging Initiative; Swedish BioFINDER study. Accurate risk estimation of \u03b2-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms. Alzheimers Dement. 2019;15(2):194\u2013204. https:\/\/doi.org\/10.1016\/j.jalz.2018.08.014.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1650_CR68","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3233\/JAD-191038","volume":"73","author":"A Ezzati","year":"2020","unstructured":"Ezzati A, Harvey DJ, Habeck C, Golzar A, Qureshi IA, Zammit AR, et al. Alzheimer\u2019s Disease Neuroimaging Initiative. Predicting amyloid-\u03b2 levels in amnestic mild cognitive impairment using machine learning techniques. J Alzheimers Dis. 2020;73(3):1211\u20139. https:\/\/doi.org\/10.3233\/JAD-191038.","journal-title":"J Alzheimers Dis"},{"issue":"24","key":"1650_CR69","doi-asserted-by":"publisher","first-page":"e2425","DOI":"10.1212\/WNL.0000000000200553","volume":"98","author":"KK Petersen","year":"2022","unstructured":"Petersen KK, Lipton RB, Grober E, Davatzikos C, Sperling RA, Ezzati A. Predicting amyloid positivity in cognitively unimpaired older adults: a machine learning approach using A4 data. Neurology. 2022;98(24):e2425-2435. https:\/\/doi.org\/10.1212\/WNL.0000000000200553.","journal-title":"Neurology"},{"issue":"1","key":"1650_CR70","doi-asserted-by":"publisher","first-page":"6954","DOI":"10.1038\/s41598-021-86114-4","volume":"11","author":"JP Kim","year":"2021","unstructured":"Kim JP, Kim J, Jang H, Kim J, Kang SH, Kim JS, et al. Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. Sci Rep. 2021;11(1):6954. https:\/\/doi.org\/10.1038\/s41598-021-86114-4.","journal-title":"Sci Rep"},{"issue":"1","key":"1650_CR71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","volume":"14","author":"AL Brand","year":"2022","unstructured":"Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: a literature review. Alzheimers Res Ther. 2022;14(1):195. https:\/\/doi.org\/10.1186\/s13195-022-01117-1.","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"1650_CR72","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma amyloid as prescreener for the earliest alzheimer pathological changes. Ann Neurol. 2018;84(5):648\u201358. https:\/\/doi.org\/10.1002\/ana.25334.","journal-title":"Ann Neurol"},{"issue":"17","key":"1650_CR73","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-1649. https:\/\/doi.org\/10.1212\/WNL.0000000000008081.","journal-title":"Neurology"},{"issue":"6","key":"1650_CR74","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/0148607114533726","volume":"38","author":"LN Chan","year":"2014","unstructured":"Chan LN, Mike LA. The science and practice of micronutrient supplementations in nutritional anemia: an evidence-based review. JPEN J Parenter Enter Nutr. 2014;38(6):656\u201372. https:\/\/doi.org\/10.1177\/0148607114533726.","journal-title":"JPEN J Parenter Enter Nutr"},{"issue":"3","key":"1650_CR75","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/ageing\/afv009","volume":"44","author":"J Lan","year":"2015","unstructured":"Lan J, Liu J, Zhao Z, Xue R, Zhang N, Zhang P, et al. The peripheral blood of A\u03b2 binding RBC as a biomarker for diagnosis of Alzheimer\u2019s disease. Age Ageing. 2015;44(3):458\u201364. https:\/\/doi.org\/10.1093\/ageing\/afv009.","journal-title":"Age Ageing"},{"issue":"7","key":"1650_CR76","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1365-2362.1995.tb01732.x","volume":"25","author":"I Engstr\u00f6m","year":"1995","unstructured":"Engstr\u00f6m I, Ronquist G, Pettersson L, Waldenstr\u00f6m A. Alzheimer amyloid beta-peptides exhibit ionophore-like properties in human erythrocytes. Eur J Clin Invest. 1995;25(7):471\u20136. https:\/\/doi.org\/10.1111\/j.1365-2362.1995.tb01732.x.","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"1650_CR77","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.neurobiolaging.2005.09.043","volume":"27","author":"J Rogers","year":"2006","unstructured":"Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27(12):1733\u20139. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.09.043.","journal-title":"Neurobiol Aging"},{"key":"1650_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1477-5956-8-11","volume":"8","author":"JG Mohanty","year":"2010","unstructured":"Mohanty JG, Shukla HD, Williamson JD, Launer LJ, Saxena S, Rifkind JM. Alterations in the red blood cell membrane proteome in alzheimer\u2019s subjects reflect disease-related changes and provide insight into altered cell morphology. Proteome Sci. 2010;8: 11. https:\/\/doi.org\/10.1186\/1477-5956-8-11.","journal-title":"Proteome Sci"},{"issue":"1","key":"1650_CR79","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000341603","volume":"2","author":"S Oma","year":"2012","unstructured":"Oma S, Mawatari S, Saito K, Wakana C, Tsuboi Y, Yamada T, et al. Changes in phospholipid composition of erythrocyte membrane in Alzheimer\u2019s disease. Dement Geriatr Cogn Dis Extra. 2012;2(1):298\u2013303. https:\/\/doi.org\/10.1159\/000341603.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"8","key":"1650_CR80","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jalz.2018.03.009","volume":"14","author":"T Iwatsubo","year":"2018","unstructured":"Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al. Japanese Alzheimer\u2019s Disease Neuroimaging Initiative. Japanese and north American Alzheimer\u2019s disease neuroimaging initiative studies: harmonization for international trials. Alzheimers Dement. 2018;14(8):1077\u201387. https:\/\/doi.org\/10.1016\/j.jalz.2018.03.009.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01650-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01650-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01650-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T07:36:27Z","timestamp":1737444987000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01650-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1650"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01650-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the local ethics committee of Oita University Hospital. Given the difficulty of obtaining informed consent for existing patient information, an information disclosure document (approved by the ethics committee and authorized by the head of Oita University Hospital) that included information on the conduct of this study and the study purpose was made publicly available on the university website. The study was registered with the University hospital Medical Information Network Clinical Trials Registry (UMIN000051776).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"NK has received consultancy\/speaker fees from Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., PDRadiopharma Inc., Otsuka Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. KS, MM, MK and YN are employees of Eisai Co., Ltd. TM, TA, and EM have no competing interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}